Developing Innovative Ligands for Nuclear Receptors to Eradicate Cancer Relapse
The aim of the Marie Sklodowska-Curie Doctoral Network “eRaDicate” is to develop new therapies against cancer stem cell-driven relapse and metastasis. The 11 doctoral candidates (DCs) of eRaDicate will be trained not only to perform original and independent research on an internationally competitive level, but will also be endowed with a creative, critical and entrepreneurial mindset, coupled with persistence in following their objectives.
News
Next Stop: Australia – Carmen Receives ÖFG Travel Grant
Carmen has been awarded a EUR 1,500 travel grant from the Austrian Science Fund (ÖFG) under the International Communication…
From Training to Podium: Carmen’s Contributions to ECDP 2026
At the 22nd European Congress on Digital Pathology (ECDP 2026) in Graz, Carmen delivered an oral presentation in the Bias in AI…
Tanya Rudola’s secondment to Shaare Zedek Medical Center
From March 22nd to March 31st, 2026, Tanya Rudola took part in a secondment in the laboratory of Prof. Yishai Ofran at Shaare Zedek Medical Center. The purpose of this placement was to gain insight into…
Consortium
The eRaDicate consortium consists of eight academic and one industrial and beneficiaries, as well as twelve associated partners to provide training and secondments.
Beneficiaries
Associated Partners
